Hexarelin before and after: Frequently asked questions

Lyophilised hexarelin tolerates ambient temperature (up to 25°C) for 48–72 hours without significant degradation. But extended exposure above 30°C or direct sunlight can denature the peptide structure. If the vial arrived warm but was reshipped within 3 days and immediately refrigerated upon arrival, it's likely still viable. If it sat in a mailbox for a week in summer heat, efficacy is compromised. Test batches from Real Peptides include temperature-monitoring strips to verify cold-chain integrity during transit.

Continue the protocol. 4 weeks is too short to assess hexarelin before and after real results accurately. IGF-1 elevation at week 4 is only 50–60% of peak levels, and lean mass accretion lags IGF-1 response by 2–3 weeks. Most measurable body composition change occurs between weeks 6–12. If you're dosing correctly (2mcg/kg twice daily, proper reconstitution, refrigerated storage), the outcome becomes visible in the second half of the protocol.

Skip the missed dose and resume at the next scheduled time. Do not double-dose to compensate. Missing a single dose drops IGF-1 slightly but doesn't reset progress. Missing 3+ consecutive doses (e.g., 36+ hours without administration) allows IGF-1 to return toward baseline, requiring 4–5 days of resumed dosing to restore elevated levels. Hexarelin before and after real results depend on cumulative IGF-1 elevation, so consistency matters more than perfection.

Hexarelin is commonly stacked with CJC-1295 Ipamorelin to extend GH pulse duration. Hexarelin provides the acute pulse, CJC-1295 prolongs it by inhibiting GH breakdown. This combination produces synergistic IGF-1 elevation (75–90% above baseline vs 60% with hexarelin alone). However, stacking increases receptor desensitisation risk, so off-cycles become mandatory every 6–8 weeks rather than 8–12 weeks.

These symptoms likely result from rapid cortisol surge (hexarelin stimulates ACTH alongside GH) or vasodilation from GH-induced nitric oxide release. Reduce the dose by 25–30% and re-test. Some subjects are high-responders who achieve adequate GH elevation at sub-standard doses. Administer with food rather than fasting to blunt the cortisol spike, though this will reduce peak GH output by approximately 30%. If symptoms persist at reduced dose, consider switching to Ipamorelin, which produces lower cortisol co-elevation.

Delayed peaks indicate either subcutaneous absorption variability (injection into adipose versus dermis) or concurrent medication interference. Insulin, for example, delays hexarelin absorption by altering local blood flow. Repeat the protocol using intramuscular injection at the deltoid site to bypass subcutaneous variables. IM administration typically advances peak timing by 10–15 minutes. If delay persists, screen for medications known to affect GH dynamics (glucocorticoids, beta-blockers, somatostatin analogs).

Administer a second challenge test 48–72 hours later using GHRH co-administration (GHRH + hexarelin combination). If GH response remains absent, this suggests primary pituitary failure rather than protocol error. If GHRH co-administration produces normal response, the original hexarelin failure likely resulted from dosing error, degraded peptide, or hypothalamic dysfunction rather than somatotroph insufficiency. Verify reconstitution concentration and storage history before concluding biological non-response.

This suggests receptor desensitization (tachyphylaxis), most commonly seen with daily or twice-daily dosing protocols. Implement a washout period of 7–10 days with no hexarelin administration, then resume at reduced frequency (every 48–72 hours instead of daily). Research measuring hexarelin before and after repeated dosing found that 48-hour intervals preserve >90% of initial GH responsiveness across 6-week protocols, while daily dosing reduces response to 60–70% of baseline by week 4.